RYTM Latest Headlines

RYTM Rallies After NICE Expands IMCIVREE Reimbursement to Adults With Bardet-Biedl Syndrome

Market Chameleon (Wed, 4-Nov 11:17 AM)

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), IDEAYA Biosciences (IDYA) and Rhythm Pharmaceuticals (RYTM)

at www.tipranks.com (Wed, 4-Nov 8:30 AM)

Rhythm Pharmaceuticals: Buy Rating Reaffirmed on Strong Imcivree Sales and MC4R Pipeline, $150 Target Maintained

at www.tipranks.com (Wed, 4-Nov 5:16 AM)

Rhythm Pharmaceuticals highlights 700+ IMCIVREE start forms as quarterly product revenue reaches $92.10 million

Market Chameleon (Tue, 3-Nov 7:40 AM)

Rhythm Pharmaceuticals GAAP EPS of -$0.61 beats by $0.10, revenue of $92.1M beats by $7.5M

at seekingalpha.com (Tue, 3-Nov 7:18 AM)

Rhythm Pharmaceuticals Q3 2026 Earnings Preview

at seekingalpha.com (Mon, 2-Nov 11:11 AM)

Record IMCIVREE Start Forms and 19% Quarterly Revenue Growth Highlight Rhythm Pharmaceuticals’ Q2 2026

Market Chameleon (Tue, 4-Aug 7:42 AM)